Gilardoni’s Radgil2, the x-ray irradiator specifically designed to prevent Transfusion Associated- Graft versus Host Disease (TA-GvHD) – a rare fatal disease connected to blood transfusions – has obtained 510k approval by US regulatory authority, the Food and Drug Administration (FDA), allowing it to be sold and operated in the USA.

Gilardoni, already a leader in the x-ray irradiator industry with equipment in Italy, Europe, Africa and the Middle East, will now be taking on demand in the most important global market x-ray irradiators for blood.

In fact, demand has increased also due to federal policy that provides incentives to substitute nuclear irradiators – which use radioactive sources – with x-ray irradiators.

The US launch is scheduled in October and is expected to provide a strong push to Radgil2’s commercial development.

Radgil2 is launching in the USA
Download Contact Us